Five point mutations in ARID1A and BRCA2 were examined in all 26 anlotinib NB patients (13 driver gene negative LUAD, 6 LUSC, and 7 driver gene positive LUAD) at BL, and the results indicated that 92% (24/26) of NB patients harbored ARID1A (A1850fs, chr 1: 26 779 439:TG/T and G766fs: chr 1: 26 762 190:TC/T) and BRCA2 (T3033fs: chr 13: 32 379 885:CA/C and chr 13: 32 379 885:C/CA) mutations, suggesting these acquired point mutations are potentially associated with anlotinib resistance (Figure 1E). This evidence concerns the gene BRCA2 and neuroblastoma.